Eisai Inc.
Clinical trials sponsored by Eisai Inc., explained in plain language.
A pharmaceutical company focused on neurology and oncology, subsidiary of Eisai Co., Ltd.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Lifeline for kids with severe epilepsy: drug access extended
Disease control AVAILABLEThis program offers continued access to rufinamide for children with Lennox-Gastaut syndrome, a severe form of epilepsy, who completed a previous study. The goal is to keep providing the medication until it becomes commercially available in Poland. Only children who were already …
Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called MORAb-202 that targets a protein (folate receptor alpha) found on some cancer cells. It is for people with ovarian, endometrial, non-small cell lung, or triple-negative breast cancer. The trial has two parts: first to find the safest dose, then …
Phase: PHASE1, PHASE2 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New pill aims to keep narcolepsy patients awake and safe
Symptom relief Recruiting nowThis study tests whether E2086, an oral tablet, can reduce excessive daytime sleepiness in adults with narcolepsy. About 64 participants will receive either the drug or a placebo for 4 weeks. Researchers will measure how long people can stay awake using a standard test, and also …
Phase: PHASE2 • Sponsor: Eisai Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Healthy men swallow radioactive pill to track Drug's journey
Knowledge-focused Recruiting nowThis early-stage study gives 10 healthy men a single dose of the experimental drug E2086 with a radioactive tracer. Researchers will measure how much of the drug appears in blood, urine, and stool over time. The goal is to understand how the body breaks down and eliminates E2086,…
Phase: PHASE1 • Sponsor: Eisai Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC